

Australian Securities Exchange
Companies Announcements Office
Exchange Centre
Level 6
20 Bridge Street
Sydney, NSW 2000

4 April 2013

Appendix 3B for Quotation of Shares to be Released from Escrow

In accordance with Listing Rule 3.10A Bioxyne Limited (**BXN** or **Company**) announces that 7,987,199 ordinary shares in the company were released from ASX escrow on 27 March 2013 and now applies for their quotation.

The escrow period was initiated on 28 March 2012 and related to voluntary/ASX imposed escrow agreements that were a requirement of the company's application for quotation following the successful completion of the takeover of Hunter Immunology Limited as announced to the market on 3 April 2012.

Following the release of these shares from escrow 14,999,046 shares will remain in escrow after 27 March 2013 and are subject to release on 4 April 2014.

The company has a total of 163,059,587 shares on issue with 148,060,541 being quoted shares. As a result of the expiration of the 31 March 2013 quoted options these shares are now the only quoted securities of the company.

In addition to the quotation of these securities the following updates to the company securities are also made which are all consistent with prior announcements of the company to the market:

- Expiration of 3,112,944 options (unquoted) on 31 March 2013;
- Expiration of 3,638,837 options (quoted) on 31 March 2013;
- Inclusion of previously omitted options from 28 March 2012 Appendix 3B lodgement which was made during the process of the company's reinstatement with the ASX last year:
 - 750,000 options \$0.40 ex expiring 25 November 2013;
 - 100,000 options \$0.20 ex expiring 3 December 2013;
 - 125,000 options \$0.40 ex expiring 24 May 2014.
- Restatement of the quoted capital table to update for the quotation of escrowed stock and also separate the 14,999,046 restricted securities (restriction ending 4 April 2014) in the unquoted section and correctly classify the Ordinary Shares class (previously all stock was noted as quoted).

An Appendix 3B seeking quotation of the shares is enclosed and all of the above updates have been included.

Yours Sincerely,



Jarrod White
Company Secretary

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Bioxyne Limited ("Bioxyne")

ABN

97 084 464 193

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued

Options to acquire Shares (**Options**)

- 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued

Securities to be marked as issued (unquoted):

- a. 750,000 Options, each exercisable at \$0.40 per Option, on or before 25 November 2013;
- b. 100,000 Options, each exercisable at \$0.20 per Option, on or before 3 December 2013;
- c. 125,000 Options, each exercisable at \$0.40 per Option, on or before 24 May 2014.

+ See chapter 19 for defined terms.

Appendix 3B

New issue announcement

- 3 Principal terms of the
+securities (e.g. if options,
exercise price and expiry date; if
partly paid +securities, the
amount outstanding and due
dates for payment; if
+convertible securities, the
conversion price and dates for
conversion)

The principal terms of each class of Options referred to in paragraphs (a) to (c) (both inclusive) of Item 2 are as set out in Item 2.

+ See chapter 19 for defined terms.

- 4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

None of the Options referred to in Item 2 will rank equally with any existing class of quoted Bioxyne securities. Further, none of the Options will entitle their respective holders to participate in any dividends in Bioxyne.

+ See chapter 19 for defined terms.

5 Issue price or consideration

The options referred to in (a) of Item 2 were originally issued on 27 November 2008 and have remained on issue since this date, however were accidentally omitted by the company in the Appendix 3B lodged on 28 March 2012 which was prepared on application of the company for reinstatement to official quotation which was granted on 3 April 2012. The Options were originally issued for Nil consideration in conjunction as Employee Share Options.

The options referred to in (b) of Item 2 were originally issued on 5 December 2008 and have remained on issue since this date, however were accidentally omitted by the company in Appendix 3B lodged on 28 March 2012 which was prepared on application of the company for reinstatement to official quotation which was granted on 3 April 2012. The Options were originally issued for Nil consideration in conjunction as Employee Share Options.

The options referred to in (c) of Item 2 were originally issued on 26 May 2009 and have remained on issue since this date, however were accidentally omitted by the company in Appendix 3B lodged on 28 March 2012 which was prepared on application of the company for reinstatement to official quotation which was granted on 3 April 2012. The Options were originally issued for Nil consideration as free options under a placement agreement with Taylor Collison from regarding a placement conducted at that time.

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

Options at (a) – (c) of Item 2 to disclose ‘as issued’, Options previously issued but were however were accidentally omitted as such by the company in Appendix 3B lodged on 28 March 2012 which was prepared on application of the company for reinstatement to official quotation which was granted on 3 April 2012.

+ See chapter 19 for defined terms.

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

As described at Item 5.

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

	Number	+Class
8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	148,060,541	Ordinary Shares

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	14,999,046	Ordinary Shares, subject to ASX imposed escrow until 4 April 2014
	1,062,000	Options each exercisable at \$0.24 per Option on or before 1 September 2013
	750,000	Options each exercisable at \$0.40 per Option, on or before 25 November 2013
	100,000	Options, each exercisable at \$0.20 per Option, on or before 3 December 2013
	2,700,000	Options each exercisable at \$0.70 per Option on or before 14 May 2014
	125,000	Options each exercisable at \$0.40 per Option, on or before 24 May 2014
	1,000,000	Options each exercisable at \$0.40 per Option on or before 1 January 2015

+ See chapter 19 for defined terms.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	As determined by the Directors of Bioxyne from time to time in accordance with Bioxyne's constitution
----	--	---

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the ⁺ securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A

⁺ See chapter 19 for defined terms.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of ⁺securities
(tick one)

(a) ☐ ⁺Securities described in Part 1

(b) ☒ All other ⁺securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 ☐ If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders

36 ☐ If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 ☐ A copy of any trust deed for the additional ⁺securities

Entities that have ticked box 34(b)

38 Number of ⁺securities for which ⁺quotation is sought

7,987,199 Shares

39 ⁺Class of ⁺securities for which quotation is sought

Ordinary Shares

⁺ See chapter 19 for defined terms.

Appendix 3B

New issue announcement

<p>40 Do the ⁺securities rank equally in all respects from the ⁺issue date with an existing ⁺class of quoted ⁺securities?</p> <p>If the additional ⁺securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>Yes, Ordinary Shares</p>				
<p>41 Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another ⁺security, clearly identify that other ⁺security)</p>	<p>End of ASX imposed restriction period on 27 March 2013</p>				
<p>42 Number and ⁺class of all ⁺securities quoted on ASX (including the ⁺securities in clause 38)</p>	<table> <tr> <th>Number</th><th>⁺Class</th></tr> <tr> <td>148,060,541</td><td>Ordinary Shares</td></tr> </table>	Number	⁺ Class	148,060,541	Ordinary Shares
Number	⁺ Class				
148,060,541	Ordinary Shares				

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those ⁺securities should not be granted ⁺quotation.

⁺ See chapter 19 for defined terms.

- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:


.....
(Director/Company secretary)

Date: 4 April 2013

Print name:

Jarrod White

== == == == ==

+ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	149,866,276
Add the following: <ul style="list-style-type: none"> Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period <p><i>Note:</i></p> <ul style="list-style-type: none"> Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	Nil 4,185,539 Nil
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil
“A”	154,051,815

+ See chapter 19 for defined terms.

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
Multiply “A” by 0.15	23,107,772
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of ⁺equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	9,007,772
“C”	
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	23,107,772
<p>Subtract “C”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	9,007,772
Total [“A” x 0.15] – “C”	<p>14,100,000</p> <p><i>[Note: this is the remaining placement capacity under rule 7.1]</i></p>

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	N/A
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	N/A
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A <i>Notes:</i> <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	N/A
“E”	N/A

⁺ See chapter 19 for defined terms.

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
“A” x 0.10 <i>Note: number must be same as shown in Step 2</i>	N/A
Subtract “E” <i>Note: number must be same as shown in Step 3</i>	N/A
Total [“A” x 0.10] – “E”	<i>Note: this is the remaining placement capacity under rule 7.1A</i>

+ See chapter 19 for defined terms.